A nurse is providing palliative care for a client who is dying. The nurse should expect the provider to prescribe which of the following medications to control excessive oral secretions?

This clinical scenario requires the application of palliative pharmacological principles to manage secretions in a dying patient. The nurse must identify which medication possesses anticholinergic properties to decrease salivary output and treat terminal respiratory congestion. Choice A rationale Scopolamine blocks muscarinic receptors in salivary glands, effectively inhibiting parasympathetic stimulation and reducing oral and bronchial secretions. This treats death rattle and terminal congestion efficiently in dying clients. Choice B rationale Epoetin alfa stimulates erythropoiesis in the bone marrow to increase red blood cell production. It does not possess anticholinergic properties and is used for anemia, not for treating terminal excess secretions. Choice C rationale Phenobarbital is a barbiturate anticonvulsant that enhances GABA-mediated inhibition in the central nervous system. It provides sedation and manages seizures but has no therapeutic effect on reducing respiratory or oral secretions. Choice D rationale Megestrol is a synthetic progestin utilized as an appetite stimulant in patients experiencing cachexia or advanced cancer. It does not affect cholinergic pathways and cannot dry up oral cavity secretions.